Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) FCF Margin (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed FCF Margin for 4 consecutive years, with 8.99% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin rose 20451.0% to 8.99% in Q4 2025 year-over-year; TTM through Dec 2025 was 95.37%, a 38747.0% increase, with the full-year FY2025 number at 95.37%, up 38747.0% from a year prior.
  • FCF Margin was 8.99% for Q4 2025 at Phathom Pharmaceuticals, up from 28.6% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 1626.57% in Q1 2022 to a low of 6491.5% in Q4 2023.
  • A 4-year average of 713.92% and a median of 158.77% in 2025 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: plummeted -691380bps in 2023, then skyrocketed 627799bps in 2024.
  • Phathom Pharmaceuticals' FCF Margin stood at 422.31% in 2022, then plummeted by -1637bps to 6491.5% in 2023, then surged by 97bps to 213.5% in 2024, then soared by 96bps to 8.99% in 2025.
  • Per Business Quant, the three most recent readings for PHAT's FCF Margin are 8.99% (Q4 2025), 28.6% (Q3 2025), and 158.77% (Q2 2025).